Authors
Tingfeng Yang, Shaohua Zhang, Danna Xie, Zhonghao Jiang, Liangkun Niu, RunSheng Chen, Zeyu He, Xinpeng Zhang, Hua Liu, Junjie Zhou, Xing Song, Baolin Qian, Mingxing Ye, Wenguang Fu
Published in
International immunopharmacology. Volume 191. Issue Pt 1. Pages 117572. Oct 22, 2026. Epub Oct 22, 2026.
Abstract
Hepatic ischemia-reperfusion injury (HIRI) is a complex clinical complication involving inflammation and multiple forms of regulated cell death, among which ferroptosis plays a critical role. Ginsenoside Re (Re) exhibits prominent antioxidant capabilities, but its exact molecular targets in HIRI are unidentified. Here, using in vivo HIRI and in vitro hypoxia/reoxygenation (H/R) models, we found that Re administration exhibited an optimal therapeutic window, significantly alleviating hepatocellular damage, inflammatory responses, and oxidative stress. Sequentially, Re suppressed ferroptosis, as characterized by reduced iron deposition, decreased lipid peroxidation, and restored expression of GPX4 and SLC7A11. Utilizing Drug Affinity Responsive Target Stability (DARTS) and 4D-DIA quantitative proteomics, we identified BRCA1-associated protein 1 (BAP1) as a direct intracellular target of Re. Re physically bound to BAP1 and down-regulated its expression, thereby relieving BAP1-mediated transcriptional suppression of SLC7A11 and bolstering glutathione synthesis. Conversely, BAP1 overexpression reversed the anti-ferroptotic and hepatoprotective effects of Re. In conclusion, our findings demonstrate that Ginsenoside Re mitigates HIRI by targeting the BAP1/SLC7A11 axis to inhibit ferroptosis, offering a promising therapeutic strategy for clinical intervention.
PMID:
42913195
Bibliographic data and abstract were imported from PubMed on 24 Oct 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 2
- Comments 0